EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

In‐utero exposure to tenofovir‐containing pre‐exposure prophylaxis and bone mineral content in HIV‐unexposed infants in South Africa

Kerusha Reddy, Kimesh L Naidoo, Carl Lombard, Zukiswa Godlwana, Alicia C Desmond, Richard Clark, James F Rooney, Glenda Gray, Dhayendre Moodley iD

Journal of the International AIDS Society · 2024-11 · 27 (11)

DOI: 10.1002/jia2.26379 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the International AIDS Society, online erschienen am 11.11.2024. Verfasst von Kerusha Reddy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Child Health, School of Clinical Medicine, University of KwaZulu Natal, Durban, South Africa. Hauptthemen laut MEDLINE: Tenofovir, Pre-Exposure Prophylaxis, HIV Infections, Bone Density. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Tenofovir disoproxil fumarate (TDF) is a common drug of choice for pre‐exposure prophylaxis (PrEP) or as a combination HIV treatment for pregnant women. In‐utero exposure to TDF was found to be associated with lower bone mineral content (BMC) in HIV‐exposed uninfected neonates. Data for infants born to women taking TDF‐PrEP are lacking. The CAP016 randomized control trial was conducted in South Africa between September 2017 and August 2021 and pregnant women either initiated TDF/FTC PrEP in pregnancy (Immediate PrEP arm‐IP) or at cessation of breastfeeding (Deferred PrEP arm‐DP). In a secondary data analysis, we evaluated BMC in HIV‐unexposed infants in the CAP016 trial in the first 18 months of life in association with maternal TDF‐PrEP use during pregnancy.

Methods

Infants born to women randomized to the IP arm or DP arm in the CAP016 clinical trial had BMC measurements of the whole body with head (WBH) and lumbar spine (LS) by dual energy X‐ray absorptiometry (DXA) at 6, 26, 50 and 74 weeks.

Results

Of 481 infants born to women enrolled in the CAP016 clinical trial, 335 (69.6%) infants had a minimum of one DXA scan of the WBH and LS between 6 and 74 weeks of age (168 IP and 167 DP). Women in the IP arm received TDF‐FTC PreP for a median of 19 weeks between initiation in pregnancy and delivery. Using a mixed linear regression model and adjusted for gestational age, sex and ever‐breastfed, the mean difference (95% CI) for BMC of the WBH between IP and DP arms were −0.74 (−8.69 to 7.20), −1.26 (−10.75 to 8.23), −9.17 (−20.02 to 1.69) and 5.02 (−6.74 to 16.78) g at 6, 26, 50 and 74 weeks ( p = 0.283). Mean differences in BMC of the LS were 0.07 (−0.10 to 0.23), 0.02 (−0.18 to 0.22), −0.14 (−0.36 to 0.09) and 0.14 (−0.11 to 0.38) g at 6, 26, 50 and 74 weeks, respectively ( p = 0.329).

Conclusions

In a randomized controlled trial, there were no differences in BMC of the WBH and LS between infants exposed to in‐utero TDF‐FTC PrEP and unexposed infants in the first 18 months of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenofovirPre-Exposure ProphylaxisHIV InfectionsBone DensityAnti-HIV AgentsHumansFemaleSouth AfricaPregnancyInfantInfant, NewbornMaleAdultPregnancy Complications, InfectiousYoung AdultPrenatal Exposure Delayed EffectsInfectious Disease Transmission, Vertical

Stichwörter der Autor:innen

bone mineral contentbreastfeedinginfantsin‐utero exposurepre‐exposure prophylaxistenofovir disoproxil fumarate

Substanzen

TenofovirAnti-HIV Agents

Autor:innen und Institutionen

  • Department of Paediatrics and Child Health, School of Clinical Medicine, University of KwaZulu Natal, Durban, South Africa.
  • King Edward VIII, Hospital Durban South Africa, Durban, South Africa.
  • Biostatistics Unit, South African Medical Research Council, Tygerberg, South Africa.
  • Division of Epidemiology and Biostatistics, Department of Global Health, University of Stellenbosch, Tygerberg, South Africa.
  • Centre for the Program of AIDS Research in South Africa (CAPRISA), Durban, South Africa.
  • Gilead Sciences Inc, Foster City, California, USA.

ORCID-Profile: Dhayendre Moodley

Zitieren

APA

Reddy, K., Naidoo, K. L., Lombard, C., Godlwana, Z., Desmond, A. C., Clark, R., Rooney, J. F., Gray, G., & Moodley, D. (2024). In‐utero exposure to tenofovir‐containing pre‐exposure prophylaxis and bone mineral content in HIV‐unexposed infants in South Africa. Journal of the International AIDS Society, 27(11). https://doi.org/10.1002/jia2.26379

Vancouver

Reddy K, Naidoo KL, Lombard C, Godlwana Z, Desmond AC, Clark R, et al. In‐utero exposure to tenofovir‐containing pre‐exposure prophylaxis and bone mineral content in HIV‐unexposed infants in South Africa. Journal of the International AIDS Society. 2024;27(11). doi:10.1002/jia2.26379

BibTeX
@article{Reddy2024,
  author = {Reddy, Kerusha and Naidoo, Kimesh L and Lombard, Carl and Godlwana, Zukiswa and Desmond, Alicia C and Clark, Richard and Rooney, James F and Gray, Glenda and Moodley, Dhayendre},
  title = {In‐utero exposure to tenofovir‐containing pre‐exposure prophylaxis and bone mineral content in HIV‐unexposed infants in South Africa},
  journal = {Journal of the International AIDS Society},
  year = {2024},
  volume = {27},
  number = {11},
  doi = {10.1002/jia2.26379}
}
Kostenlos starten →